- Home
- IONR vs PBYI Comparison
IONR vs PBYI Comparison
Compare IONR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- PBYI
- Stock Information
- Founded
- IONR 2001
- PBYI 2010
- Country
- IONR Australia
- PBYI United States
- Employees
- IONR N/A
- PBYI N/A
- Industry
- IONR
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- IONR
- PBYI Health Care
- Exchange
- IONR Nasdaq
- PBYI Nasdaq
- Market Cap
- IONR 171.1M
- PBYI 176.1M
- IPO Year
- IONR N/A
- PBYI N/A
- Fundamental
- Price
- IONR $4.20
- PBYI $2.59
- Analyst Decision
- IONR
- PBYI Strong Buy
- Analyst Count
- IONR 0
- PBYI 1
- Target Price
- IONR N/A
- PBYI $7.00
- AVG Volume (30 Days)
- IONR 8.7K
- PBYI 352.8K
- Earning Date
- IONR 01-01-0001
- PBYI 10-31-2024
- Dividend Yield
- IONR N/A
- PBYI N/A
- EPS Growth
- IONR N/A
- PBYI N/A
- EPS
- IONR N/A
- PBYI 0.18
- Revenue
- IONR N/A
- PBYI $219,143,000.00
- Revenue This Year
- IONR N/A
- PBYI N/A
- Revenue Next Year
- IONR N/A
- PBYI N/A
- P/E Ratio
- IONR N/A
- PBYI $13.95
- Revenue Growth
- IONR N/A
- PBYI N/A
- 52 Week Low
- IONR $2.90
- PBYI $2.13
- 52 Week High
- IONR $6.50
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- IONR 57.27
- PBYI 45.60
- Support Level
- IONR $3.76
- PBYI $2.23
- Resistance Level
- IONR $4.48
- PBYI $2.42
- Average True Range (ATR)
- IONR 0.28
- PBYI 0.15
- MACD
- IONR 0.03
- PBYI 0.05
- Stochastic Oscillator
- IONR 51.68
- PBYI 76.60
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S. based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.